#
**Incannex Healthcare (Nasdaq: IXHL)** reported 2025 progress and a 2026 outlook highlighting clinical, regulatory and financial momentum. Key 2025 achievements include **two positive Phase 2** readouts (IHL-42X for OSA and PSX-001 for GAD), **FDA Fast Track designation** for IHL-42X, and reported reductions in AHI of up to **83%**. The company said it has > **$70 million** in cash, completed a **$12.5 million** private placement, eliminated Series A warrants, and authorized a **$20 million** share repurchase program, providing runway well into 2027. 2026 priorities include advancing IHL-42X toward later-stage development and progressing PSX-001 clinical and regulatory planning.
# Positive
* Two positive **Phase 2** clinical readouts in 2025
* **FDA Fast Track** designation granted for IHL-42X
* Cash balance reported at > **$70 million**, runway into 2027
* Completed **$12.5 million** private placement financing
* Authorized **$20 million** share repurchase program
* Eliminated Series A warrants, removing legacy dilution overhang
# Negative
* No near-term revenue or commercialization milestone disclosed
* Advancement to later-stage trials may require successful regulatory steps